Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Biotechnology

Healthcare
$3.72 +1.71%

+$0.06 today

Market cap
$284.14M
Beta
2.92
P/E (TTM)
-3.6
EPS (TTM)
-$1.00
52W Low $2.83High $15.74

Volume 0.63M

Average 1.78M

FULC Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Fulcrum Therapeutics, Inc.NASDAQ: FULC

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 19.2% from a year ago

Cash & equivalents stood at $50.26M at the end of Q1 FY2026, up 19.2% from a year earlier and down 74.6% from the prior quarter. Over 3 fiscal years it compounded at +77.9% a year.

Context

  • Cash & equivalents amounted to 14.5% of total assets at the end of Q1 FY2026, down 2.9 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +19.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$50.26M-74.6% QoQ
Last fiscal yearDec 2025
$197.53M+239.3% YoY
Year agoMar 2025
$42.18M+19.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.2%——
1 year+239.3%——
3-year CAGR+77.9%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
197.53M USD
Year-over-year change
+239.3%
4-year CAGR
+53.7%

Cash & Equivalents vs competitors

How FULC compares with its peers on the latest reported figures

  • FULC's Mar 2026 cash & equivalents of $50.26M is the 6th highest of the 10 companies compared; the peer median is $55.17M.
  • Its year-over-year change of +19.2% is the 3rd highest of 10, against a peer median of -15.7%.
  • Cash & equivalents amounts to 14.5% of total assets for FULC, versus a peer median of 47.2%.
FULC Competitors Peer median
Cash & Equivalents for FULC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BCYCBicycle Therapeutics plcMar 2026$559.47M -29.4%+22.8%85.8%
ADCTADC Therapeutics S.A.Mar 2026$231.01M +18.6%-7.1%79.2%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$147.07M +15.9%-8.8%95.6%
NGNENeurogene Inc.Mar 2026$124.16M +75.4%+8.2%47.2%
CMPXCompass Therapeutics, Inc.Mar 2026$55.17M +34.4%-4.3%26.9%
FULCFulcrum Therapeutics, Inc.Mar 2026$50.26M +19.2%+77.9%14.5%
LXRXLexicon Pharmaceuticals, Inc.Mar 2026$38.09M -39.4%-9.5%14.2%
LCTXLineage Cell Therapeutics, Inc.Mar 2026$35.94M -24.9%+53.2%32.8%
OCGNOcugen, Inc.Mar 2026$31.86M -15.7%-37.9%56.0%
OMEROmeros CorporationMar 2026$1.91M -55.3%-4.3%0.7%
Peer median (excluding FULC) $55.17M-15.7%-4.3%47.2%

Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents35.41M35.1M25.56M58.21M197.53M
Short-term Investments182.75M167.82M210.66M182.81M154.77M
Net Receivables4.11M1.08M2.25M3.34M1.07M
Inventory(473K)0000
Other Current Assets00005.17M
Total Current Assets226M207.52M242.2M249.92M357.48M
Property, Plant & Equipment (Net)7.37M15.97M12.39M9.58M7.07M
Goodwill00000
Intangible Assets00000
Long-term Investments1.09M1.09M000
Tax Assets00000
Other Non-current Assets542K2.1M3.1M1.21M1.74M
Total Non-current Assets9M19.17M15.5M10.8M8.8M
Total Assets235M226.69M257.69M260.72M366.28M
Account Payables4.79M3.64M2.76M1.16M1.59M
Short-term Debt02.6M000
Tax Payables00000
Deferred Revenue4.71M934K000
Other Current Liabilities4.71M5.34M396K463K258K
Total Current Liabilities19.2M16.73M13.68M11.04M13.05M
Long-term Debt00004.04M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)0197K000
Other Non-current Liabilities4.26M0197K197K197K
Total Non-current Liabilities4.26M11.02M8.83M6.64M4.24M
Total Liabilities23.46M27.74M22.5M17.68M17.28M
Common Stock41K52K62K54K67K
Retained Earnings(302.47M)(412.34M)(509.67M)(519.4M)(594.28M)
Accumulated OCI(397K)(797K)(136K)130K174K
Other Stockholders Equity00000
Minority Interest00000
Total Equity211.54M198.94M235.19M243.03M349M
Total Debt013.42M10.82M8.63M6.44M
Net Debt(35.41M)(21.68M)(14.74M)(49.58M)(191.09M)

Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Intrinsic Alpha fair value

Locked

Current Price

$3.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.